Appointment dossier — Squamous Cervical Carcinoma

Compounds studied in Squamous Cervical Carcinoma

• Trastuzumab Deruxtecan — Human evidence · 1 positive · PMID 39639215
• Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT05768178 · Phase 2 / Phase 3 — DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (United Kingdom)
• NCT06022757 · Phase 1 / Phase 2 — Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) (China)
• NCT06330064 · Phase 2 — A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) (United States)
• NCT06526819 · Phase 1 / Phase 2 — SMP-3124LP in Adults With Advanced Solid Tumors (United States)
• NCT06943820 · Phase 1 / Phase 2 — AK129 Combination Therapy for Advanced Solid Tumors (China)
• NCT06172478 · Phase 2 — A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (United States)
• NCT06781983 · Phase 1 — Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors (United States)
• NCT06270706 · Phase 1 — A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors (United States)
• NCT07584499 · Phase 1 — Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors (China)
• NCT04429542 · Phase 1 — Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors (United States)
• NCT06022029 · Phase 1 — A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (United States)
• NCT06423235 · Phase 4 — Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules (China)
• NCT05815927 · Phase 3 — Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer (Belgium)
• NCT06064877 · Phase 3 — A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (United States)
• NCT05333523 · Phase 3 — Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. (Netherlands)
• NCT04138212 · Phase 3 — Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) (China)
• NCT05342792 · Phase 3 — Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (China)
• NCT05367206 · Phase 3 — Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial (China)

Most-relevant first: trials that name Squamous Cervical Carcinoma, then broader trials you may still qualify for. 648 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. I've read that Trastuzumab Deruxtecan has been studied in people for Squamous Cervical Carcinoma — what's the evidence, and is it an option or available in a trial for me?
2. I've read that Trastuzumab-Deruxtecan (T-Dxd) has been studied in people for Squamous Cervical Carcinoma — what's the evidence, and is it an option or available in a trial for me?
3. Of the open trials I found (for example NCT05768178), am I eligible for any — here or at a larger cancer center?
4. What is my exact diagnosis — the type, subtype, stage, and grade?
5. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
6. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
7. What is the goal of treatment for me — cure, long-term control, or comfort?
8. What are all of my standard treatment options, and what does each one involve?
9. What is the realistic benefit of each option, in actual numbers?
10. What are the most common and the most serious side effects, and how are they managed?
11. How will we know if treatment is working, and how often will I be scanned or tested?
12. If the first treatment doesn't work, what are the next options?
13. Are there gentler options if I want to prioritize quality of life?
14. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
15. Is my case reviewed by a multidisciplinary tumor board?
16. Would a second opinion at a center that treats my cancer often be worthwhile?
17. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
18. Which symptoms are emergencies, and who do I call after hours?
19. Should I see palliative or supportive care alongside my treatment?
20. How will treatment affect my daily life, work, and (if it matters to me) fertility?
21. What can I safely do myself — diet and activity — and is anything I'm taking risky?
22. What will treatment cost, and is financial assistance available?